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  EVIDENCE-BASED ANSWER 
Most children with attention deficit/hyperactivity disorder (ADHD) who are started on methylphenidate will 
respond favorably to a dose increase if the initial dose does not sufficiently reduce symptoms. Once titrated to 
an effective maintenance dose, frequent follow-up is necessary to monitor for side effects and recurring 
symptoms. The dose of methylphenidate can then be increased further for better symptom control, which may 
be warranted in most cases. 
In some children, methylphenidate may not achieve response even at high doses or may cause intolerable side 
effects. For these children, start a different stimulant medication (strength of recommendation: B, based on 
extrapolation of 1 randomized controlled trial). 
  EVIDENCE SUMMARY 
Most studies of ADHD medication have lasted fewer than 4 months. The National Institute of Mental Health 
Collaborative Multisite Multimodal Treatment Study of Children with Attention Deficit/Hyperactivity Disorder 
(known as the MTA study) is the longest treatment study of children to date. This study—a 28-day, double-
blind placebo-controlled trial—enrolled children aged 7 to 9 years with ADHD and compared 4 treatment 
strategies (including medication and behavioral interventions) over 14 months.1-3 
Of particular interest was the dose-titration evaluation at the beginning of the study. Daily dose-switching 
titration of methylphenidate was used to identify the optimal starting dose for each child assigned to receive 
medication. In all, 289 children were randomized to receive methylphenidate, and 256 completed the titration 
(17 children refused to take medication, 1 moved, 4 had side effects, 4 had missing data, and 7 stopped mid-
titration because of inability to follow the titration protocol). 
Of the 256 children who completed titration, 198 (77%) responded favorably to 1 of the following doses: low (15 
mg/day), intermediate (25 mg/day), or high (35 mg/day for children weighing less than 25 kg; or 50 mg/day for 
children weighing 25 kg or more). Of the remaining 23%, 32 children responded best to placebo and 26 were 
methylphenidate nonresponders and were subsequently placed on dextroamphetamine. 
Children who responded to methylphenidate entered the 13-month maintenance phase on the optimal dose 
identified in the titration trial. They were monitored by monthly re-examination and review of information from 
parents and teachers regarding ADHD symptoms and potential drug side effects. The dose was changed if 
symptoms were not well controlled or if side effects were present. Subsequently, if no effective and well-
tolerated dose of methylphenidate could be identified, the drug was deemed ineffective for that child and was 
replaced by another medication. 
Of the children who responded to methylphenidate, 88% were still taking it at the end of the maintenance trial; 
29% were still taking the titration-determined dose of methylphenidate, 18% took a lower dose, and 41% took a 
higher dose as their “optimal” dose, at which there were no clinically significant symptoms, or “no room for 
improvement.” The mean dose increased from 31 mg/day at the start to 34 mg/day at the end of the study. Of 
the 430 total changes in dose made during the maintenance period, 62% were dose increases. 
While commendable for its design and large study population, the MTA study had several limitations. The 
titration trial’s complex method of determining each child’s “best dose” may not be feasible in clinical practice. 
Furthermore, the study enrolled only children aged 7 to 9 years, while ADHD affects a much broader age 
range. Finally, the chronic nature of ADHD limits the generalizability of this study beyond 14 months. Additional 
long-term studies are needed. 
  RECOMMENDATIONS FROM OTHERS 
The most common strategy for managing children taking methylphenidate is to start with a low dose and 
gradually adjust upward, as required by residual symptoms and as allowed by side effects. This escalating-
dose titration reflects typical practice in the United States, as described in several clinical guides.4,5 The 
Physician’s Desk Reference states that the maximum total daily dose is 60 mg for methylphenidate, and 
experts often limit the upper range to 25 mg for a single dose.6 
The American Academy of Child and Adolescent Psychiatry suggests using a consistent titration schedule with 
weekly increases in increments of 5–10 mg per dose to achieve symptom control. Alternatively, a fixed-dose 
titration trial similar to that found in the MTA study may be employed, in which a full set of different doses is 
switched on a weekly basis. If the top recommended dose does not help, a change in drug or psychosocial 
intervention may be more beneficial than an increase in methylphenidate dose.6 
CLINICAL COMMENTARY 
John  Hill,  DO 
University of Colorado Health Sciences Center,Denver 
It is disheartening to watch a bright child receive D’s in school just because he or she 
cannot pay attention. Treating children with ADHD is one of the most clinically rewarding 
behavioral issues we can address as primary care physicians. 
The escalating-dose titration and effective maintenance of methylphenidate can seem 
intimidating. We fear the side effects and are unsure if raising the dose of methylphenidate 
will have any benefits. 
Clearly, it is shown that raising the methylphenidate dose brings further benefits for most 
children, but short-acting forms (such as Ritalin) frequently have intolerable side effects. 
Several long-acting forms of methylphenidate (Concerta, Metadate CD, Methylin ER, and 
Ritalin SR) are now on the market. This allows us to raise the dose as high as 54–60 
mg/day with much less drug intolerance. For children who are benefiting from 
methylphenidate but cannot tolerate the side effects, consider the long-acting form. 
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